

Cardium Therapeutics, Inc.  
Form 8-K  
October 20, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**DATE OF REPORT (Date of earliest event reported): October 14, 2009**

**001-33635**

**(Commission file number)**

**CARDIUM THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

Edgar Filing: Cardium Therapeutics, Inc. - Form 8-K

**Delaware**  
(State of incorporation)

**27-0075787**  
(IRS Employer Identification No.)

**12255 El Camino Real, Suite 250**

**San Diego, California 92130**  
(Address of principal executive offices)

**(858) 436-1000**  
(Registrant's telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01 OTHER EVENTS.**

On October 14, 2009, Cardium Therapeutics, Inc. ( Cardium ) issued a press release reporting positive data from its Matrix Phase 2b clinical trial of Excellerate for the potential treatment of patients with chronic non-healing diabetic foot ulcers. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. On October 14, 2009, Cardium announced plans for the commercial development of a new product candidate Excellagen , a collagen-based topical gel for use by physicians in conjunction with surgical debridement of wounds in patients with chronic or non-chronic diabetic foot ulcers. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated by reference herein. On October 15, 2009, Cardium issued a press release announcing the publication of positive findings from the Excellerate Phase 1/2 clinical study in the Journal of Wound Repair and Regeneration. A copy of the press release is attached hereto as Exhibit 99.3 and incorporated by reference herein.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibits.

99.1 Press Release of Cardium issued on October 14, 2009.

99.2 Press Release of Cardium issued on October 14, 2009

99.3 Press Release of Cardium issued on October 15, 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CARDIUM THERAPEUTICS, INC.**

Date: October 20, 2009

By: */s/* CHRISTOPHER J. REINHARD  
**Christopher J. Reinhard**  
**Chief Executive Officer**